{"first_name":"James","last_name":"Gilligan","permalink":"james-gilligan","crunchbase_url":"http://www.crunchbase.com/person/james-gilligan","homepage_url":null,"birthplace":null,"twitter_username":null,"blog_url":null,"blog_feed_url":null,"affiliation_name":"Unaffiliated","born_year":null,"born_month":null,"born_day":null,"tag_list":null,"alias_list":null,"created_at":"Fri Mar 16 13:44:22 UTC 2012","updated_at":"Fri Mar 16 13:47:40 UTC 2012","overview":"<p>Prior to joining Tarsa, Dr. James Gilligan held positions of increasing responsibility for nearly 30 years at Unigene, where he led the development of the oral calcitonin product now licensed to Tarsa.  He serves as vice president of product development at Unigene, where he was project leader for the oral and nasal calcitonin programs, as well as the oral parathyroid hormone and site-directed bone growth programs.  Dr. Gilligan was responsible for leading the clinical programs and successful U.S. and European regulatory registrations for the nasal calcitonin product Fortical® Nasal Spray and the injectable calcitonin product Forcaltonin® Injection.  Dr. Gilligan holds a Ph.D. in pharmacology toxicology from the University of Connecticut and a master’s degree in international business from the Stillman School of Business at Seton Hall University.</p>","image":null,"degrees":[],"relationships":[{"is_past":false,"title":"Founder & Chief Scientific Officer","firm":{"name":"Tarsa Therapeutics","permalink":"tarsa-therapeutics","type_of_entity":"company","image":{"available_sizes":[[[150,80],"assets/images/resized/0007/4051/74051v1-max-150x150.jpg"],[[250,134],"assets/images/resized/0007/4051/74051v1-max-250x250.jpg"],[[345,186],"assets/images/resized/0007/4051/74051v1-max-450x450.jpg"]],"attribution":null}}}],"investments":[],"milestones":[],"video_embeds":[],"external_links":[],"web_presences":[]}